Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Shafran

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsAlessandra Mangia, Scott Milligan, Mandana Khalili, et al.
Hepatology International|July 24, 2015
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trialMitchell L Shiffman, Hugo Cheinquer, Christoph P Berg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyJordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsAlessandra Mangia, Scott Milligan, Mandana Khalili, et al.
Hepatology International|July 24, 2015
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trialMitchell L Shiffman, Hugo Cheinquer, Christoph P Berg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyJordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.
Pageof 4